Papers - KIYOI, Hitoshi
-
Simple and Efficient Generation of Virus-specific T Cells for Adoptive Therapy Using Anti-4-1BB Antibody. Reviewed
Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M.
J Immunother. Vol. 38 page： 62-70 2015
-
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Reviewed
Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG).
Blood Cancer J. Vol. 4 page： e252 2014.10
-
Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression. Reviewed
Shimada K, Tomita A, Saito S, Kiyoi H.
Br J Haematol Vol. 166 page： 455-457 2014
-
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Reviewed
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; The Japan Adult Leukemia Study Group.
Cancer Sci Vol. 105 page： 97-104 2014
-
De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity. Reviewed
Tokunaga T, Tomita A, Sugimoto K, Shimada K, Iriyama C, Hirose T, Shirahata-Adachi M, Suzuki Y, Mizuno H, Kiyoi H, Asano N, Nakamura S, Kinoshita T, Naoe T.
Cancer Sci Vol. 105 page： 35-43 2014
-
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. Reviewed
Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K, Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi D, Kiyoi H, Miyazaki Y, Emi N, Kobayashi Y, Ohno R, Naoe T.
Cancer ( 119 ) page： in press 2013
-
GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. Reviewed
Niimi K, Kiyoi H, Ishikawa Y, Hayakawa F, Kurahashi S, Kihara R, Tomita A and Naoe T.
Leukemia Research Reports Vol. 2 page： 21-25 2013
-
Mutations in the nucleolar phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcription factor MEF/ELF4 in leukemia cells and potentiates transformation. Reviewed
Ando K, Tsushima H, Matsuo E, Horio K, Tominaga-Sato S, Imanishi D, Imaizumi Y, Iwanaga M, Itonaga H, Yoshida S, Hata T, Moriuchi R, Kiyoi H, Nimer S, Mano H, Naoe T, Tomonaga M, Miyazaki Y.
J Biol Chem Vol. 288 page： 9457-9467 2013
-
Gene mutations of acute myeloid leukemia in the genome era. Invited Reviewed
Naoe T, Kiyoi H
Int J Hematol Vol. 97 page： 165-174 2013
-
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. Reviewed
Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T, Nakaseko C, Ishigatsubo Y, Shinagawa K, Takeshita A, Miyazaki Y, Ohnishi K, Miyawaki S, Naoe T; Japan Adult Leukemia Study Group.
Cancer Sci Vol. 104 page： 1339-45 2013
-
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Invited Reviewed
Tomita A, Kiyoi H, Naoe T.
Int J Hematol Vol. 97 page： 717-725 2013
-
Guest editorial: efficacy of and resistance to molecularly targeted therapy for myeloid malignancies. Invited Reviewed
Kiyoi H.
Int J Hematol Vol. 97 page： 681-682 2013
-
CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Reviewed
Shimada K, Tomita A, Minami Y, Abe A, Hind CK, Kiyoi H, Cragg MS, Naoe T.
Exp Hematol Vol. 40 page： 724-737 2012
-
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. Reviewed
Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R.
Int J Hematol Vol. 96 page： 84-93 2012
-
Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Reviewed
Doisaki S, Muramatsu H, Shimada A, Takahashi Y, Mori-Ezaki M, Sato M, Kawaguchi H, Kinoshita A, Sotomatsu M, Hayashi Y, Furukawa-Hibi Y, Yamada K, Hoshino H, Kiyoi H, Yoshida N, Sakaguchi H, Narita A, Wang X, Ismael O, Xu Y, Nishio N, Tanaka M, Hama A, Koike K, Kojima S.
Blood Vol. 120 page： 1485-8 2012
-
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Reviewed
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T.
Cancer Sci Vol. 103 ( 11 ) page： 1974-1978 2012
-
Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. Reviewed
Iriyama C, Tomita A, Hoshino H, Shirahata M, Furukawa-Hibi Y, Yamada K, Kiyoi H, Naoe T.
Biochem Biophys Res Commun Vol. 419 page： 662-9 2012
-
Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
Hama A, Muramatsu H, Makishima H, Sugimoto Y, Szpurka H, Jasek M, O'Keefe C, Takahashi Y, Sakaguchi H, Doisaki S, Shimada A, Watanabe N, Kato K, Kiyoi H, Naoe T, Kojima S, Maciejewski JP.
Br J Haematol Vol. 156 page： 316-325 2012
-
Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin. Reviewed
Kajiguchi T, Katsumi A, Tanizaki R, Kiyoi H, Naoe T
Eur J Haematol Vol. 88 page： 314-20 2012
-
Long-term outcome of imatinib therapy, with assessment of its dosage and blood levels, for chronic myelogenous leukemia. Reviewed
Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T.
Cancer Sci Vol. 103 page： 1071-1078 2012